Finance

Beta
Lists
TORNTPHARM:NSE
Torrent Pharmaceuticals Ltd
₹4,418.00
-2.64%
(-119.80) 1D
May 29, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for TORNTPHARM...
Open
₹4,554.80
High
₹4,575.00
Low
₹4,356.10
Mkt. cap
1.50T
Avg. vol.
303.48K
Volume
3.00M
Dividend
0.86%
Quarterly dividend
₹9.50
Ex-dividend date
May 29, 2026
P/E ratio
69.12
52-wk high
₹4,712.90
52-wk low
₹3,102.00
EPS
₹63.92
Shares outstanding
170.00M
No. of employees
17K
Open
₹4,554.80
High
₹4,575.00
Low
₹4,356.10
Mkt. cap
1.50T
Avg. vol.
303.48K
Volume
3.00M
Dividend
0.86%
Quarterly dividend
₹9.50
Ex-dividend date
May 29, 2026
P/E ratio
69.12
52-wk high
₹4,712.90
52-wk low
₹3,102.00
EPS
₹63.92
Shares outstanding
170.00M
No. of employees
17K
News stories
From sources across the web
Profile
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics. Wikipedia
About Torrent Pharmaceuticals Ltd
CEO-
Employees17.1K
Founded1959
HeadquartersAhmedabad, Gujarat, India
SectorPharmaceutical industry
Websitetorrentpharma.com
Last report
May 22, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹12.85 / ₹16.19
-20.61%miss
Revenue / Est. (INR)
41.97B / 38.90B
+7.89%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
31.78B
33.02B
33.03B
41.97B
Cost of goods sold
7.74B
8.00B
7.99B
10.15B
Cost of revenue
7.74B
8.00B
7.99B
10.15B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.05B
6.27B
6.51B
7.88B
Operating expense
15.73B
16.23B
16.22B
23.34B
Total operating expenses
23.47B
24.23B
24.21B
33.49B
Operating income
8.31B
8.79B
8.82B
8.48B
Other non operating income
-370.00M
-270.00M
-130.00M
-170.00M
EBT including unusual items
7.38B
7.91B
8.14B
5.29B
EBT excluding unusual items
7.38B
8.04B
8.24B
5.95B
Income tax expense
1.90B
2.00B
1.79B
1.65B
Effective tax rate
25.75%
25.28%
21.99%
31.19%
Other operating expenses
7.67B
7.92B
7.65B
10.38B
Net income
5.48B
5.91B
6.35B
3.89B
Net profit margin
17.24%
17.90%
19.22%
9.27%
Earnings per share
16.19
17.75
19.00
12.85
Interest and investment income
-
-
-
-
Interest expense
-560.00M
-480.00M
-450.00M
-2.36B
Net interest expenses
-560.00M
-480.00M
-450.00M
-2.36B
Depreciation and amortization charges
2.01B
2.04B
2.06B
5.08B
EBITDA
10.18B
10.82B
10.69B
11.28B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer